Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: Cellular iron chelation mediating cytotoxic activity

Chemical Research in Toxicology

Volumn 21, Issue 9, 2008, Pages 1878-1889

  Opletalová, Veronika ^a   Kalinowski, Danuta S ^b   Vejsová, Marcela ^c   Kuneŝ, Jir̂í ^a   Pour, Milan ^a   Jampílek, Josef ^d   Buchta, Vladimír ^c   Richardson, Des R ^b  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d Zentiva Prague   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOPHENONE N,N DIMETHYLTHIOSEMICARBAZONE; ACETOPHENONE THIOSEMICARBAZONE; AMPHOTERICIN B; CARRIER PROTEIN; DEFERASIROX; DEFERIPRONE; FLUCONAZOLE; IRON; LIGAND; METAL ION; N,N DIMETHYL 2 (1 PYRAZIN 2 YLETHYLIDENE)HYDRAZINECARBOTHIOAMIDE; THIOSEMICARBAZONE; TRANSFERRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL PROLIFERATION; CHELATION; COMPLEX FORMATION; CYTOTOXICITY; DRUG MECHANISM; FUNGAL STRAIN; HUMAN; HUMAN CELL; IN VITRO STUDY; IRON CHELATION; METAL BINDING; NEUROEPITHELIOMA; NONHUMAN; OXIDATION REDUCTION REACTION; SERUM; SUBSTITUTION REACTION; SYNTHESIS;

ABSIDIA; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; ASPERGILLUS FUMIGATUS; CANDIDA; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; IRON; IRON CHELATING AGENTS; LIGANDS; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; STEREOISOMERISM; THIOSEMICARBAZONES; TRICHOPHYTON; TRICHOSPORON; TUMOR CELLS, CULTURED;

FUNGI;

EID: 53549110231     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx800182k     Document Type: Article

References (58)

1. Kalinowski, D. S., and Richardson, D. R. (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57, 547-583.
2. Kalinowski, D. S., and Richardson, D. R. (2007) Future of toxicology - iron chelators and differing modes of action and toxicity: The changing face of iron chelation therapy. Chem. Res. Toxicol. 20, 715-720.
3. Beraldo, H., and Gambino, D. (2004) The wide pharmacological versatility of semicarbazones, thiosemicarbazones and their metal complexes. Mini Rev. Med. Chem. 4, 31-39.
4. Smee, D. F., and Sidwell, R. W. (2003) A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 57, 41-52.
5. Pandeya, S. N., Sriram, D., Nath, G., and DeClercq, E. (1999) Synthesis, antibacterial, antifungal and anti-HTV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4′-chlorophenyl)thiazol- 2-yl] thiosemicarbazide. Eur. J. Pharm. Sci. 9, 25-31.
6. Chohan, Z. H., Pervez, H., Rauf, A., Khan, K. M., and Supuran, C. T. (2004) Isatin-derived antibacterial and antifungal compounds and their transition metal complexes. J. Enzyme Inhib. Med. Chem. 19, 417-423.
7. Yu, Y., Wong, J., Lovejoy, D. B., Kalinowski, D. S., and Richardson, D. R. (2006) Chelators at the cancer coalface: Desferrioxamine to triapine and beyond. Clin. Cancer Res. 12, 6876-6883.
8. Finch, R. A., Liu, M.-C., Grill, S. P., Rose, W. C., Loomis, R., Vasquez, K. M., Cheng, Y.-C., and Sartorelli, A. C. (2000) Triapiiie (3-anTinopyridine-2-carboxaldehyde-thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol 59, 983-991.
9. Yen, Y., Margolin, K., Doroshow, J., Fishman, M., Johnson, B., Clairmont, G, Sullivan, D., and Sznol, M. (2004) A phase I trial of 3-aminopyridine-2- carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother. Pharmacol. 54, 331-342.
10. Chen, R.-W., Yao, C., Lu, X.-C., Jiang, Z.-G., Whipple, R., Liao, Z., Ghanbari, H. A., Almassian, B., Tortella, F. C., and Dave, J. R. (2005) PAN-811 (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), a novel neuroprotectant, elicits its function in primary neuronal cultures by up-regulating BCL-2 expression. Neuroscience 135, 191-201.
11. Jiang, Z.-G., Lebowitz, M. S., and Ghanbari, H. A. (2006) Neuroprotective activity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811), a cancer therapeutic agent. CNS Drug Rev. 12, 77-90.
12. Chen, R.-W., Lu, X.-C., Yao, C., Liao, Z., Jiang, Z.-G., Wei, H., Ghanbari, H. S., Tortella, F. C., and Dave, J. R. (2007) PAN-811 provides neuroprotection against glutamate toxicity by suppressing activation of JNK and p38 MAPK. Neurosci. Lett 422, 64-67.
13. Chaston, T. B., Lovejoy, D. B., Watts, R. N., and Richardson, D. R. (2003) Examination of the anti-proliferanve activity of iron chelators: Multiple cellular targets and the different mechanism of action of triapine compared to desferrioxamine and the potent PIH analogue 311. Clin. Cancer Res. 9, 402-414.
14. Whitnall, M., Howard, J., Ponka, P., and Richardson, D. R. (2006) A class of iron chelators with a wide spectrum of antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl. Acad Sci. U.S.A. 103, 14901-14906.
15. Kalinowski, D. S., Yu, Y., Sharpe, P. C., Islam, M., Liao, Y.-T., Lovejoy, D. B., Kumar, K, Bernhardt, P. V., and Richardson, D. R. (2007) Design, synthesis and characterization of novel iron chelators: Structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogs as potent anti-tumor agents. J. Med. Chem. 50, 3716-3729.
16. Richardson, D. R., Sharpe, P. C., Lovejoy, D. B., Senaratne, D., Kalinowski, D. S., Islam, M., and Bernhardt, P. V. (2006) Dipyridyl thiosemicarbazone chelators with potent and selective anti-tumor activity form iron complexes with marked redox activity. J. Med. Chem. 49, 6510-6521.
17. Yuan, J., Lovejoy, D. B., and Richardson, D. R. (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment Blood 104, 1450-1458.
18. Dolezal, M., Palek, L., Vinsova, J., Buchta, V., Jampilek, J., and Kralova, K. (2006) Substituted pyrazinecarboxamides: Synthesis and biological evaluation. Molecules 11, 242-256.
19. Vogelzang, N. J., Mick, R., Janisch, L., Berezin, F., Schilsky, R. L., and Ratain, M. J. (1994) Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Cancer Res. 54, 114-119.
20. Shao, J., Zhou, B., Di Bilio, A. J., Zhu, L., Wang, T., Qi, C., Shih, J., and Yen, Y. (2006) A ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Cancer Ther. 5, 586-592.
21. Aguirre, G-, Boiani, L., Cerecetto, H., Fernandez, M., Gonzalez, M., Denicola, A., Otero, L., Gambino, D., Rigol, C., Olea-Azar, C., and Faundez, M. (2004) In vitro activity and mechanism of action against the protozoan parasite Trypanosoma cruzi of 5-nitrofuryl containing thiosemicarbazones. Bioorg. Med Chem. 12, 4885-4893.
22. Richardson, D. R., and Bernhardt, P. V. (1999) Crystal and molecular structure of 2-hydroxy-l-naphthylaldehyde isonicotinoyl hydrazone (NTH) and its iron(III) complex: An iron chelator with anti-proliferanve activity. J. Biol. Inorg. Chem. 4, 266-273.
23. Opletalova, V., Patel, A., Boulton, M., Dundrova, A., Lacinova, E., Prevorova, M., Appeltauerova, M., and Coufalova, M. (19%) 5-AIkyl-2- pyrazinecarboxamides, 5-alkyl-2-pyrazinecarbonitriles and 5-alkyl-2- acetylpyrazines as synthetic intermediates for antiinflammatory agents. Collect. Czech. Chem. Commun. 61, 1093-1101.
24. Kucerova-Chlupacova, M., Opletalova, V., Jampilek, J., Dolezel, J., Pour, M., Kunes, J., and Vorisek, V. (2008) New hydrophobicity constants of substituents in pyrazine rings derived from RP-HPLC study. Collect. Czech. Chem. Commun. 73, 1-18.
25. Kushner, S., Dalalian, H., Sanjurjo, J. L., Bach, F. L., Jr., Safir, S. R., Smith, V. K., Jr., and Williams, J. H. (1952) Experimental chemotherapy of tuberculosis. II. The synthesis of pyrazinamides and related compounds. J. Am. Chem. Soc. 74, 3617-3621.
26. Easmon, J., Heinisch, G., Hölzer, W., and Rosenwirth, B. (1992) Novel thiosemicarbazones derived from formyl- and acyldiazines: Synthesis, effect on cell proliferation, and synergism with antiviral agents. J. Med Chem. 35, 3288-3296.
27. Milczarska, B., Foks, H., Trapkowski, Z., Mylzynska-Kolaczek, A., Janowiec, M., Zwolska, Z., and Andrzejczyk, Z. (1998) Studies on pyrazine derivatived XXXII. Synthesis and tuberculostatic activity of acetylpyrazine thiosemicarbazone derivatives. Acta. Pol. Pharm. Drug Res. 55, 289-295.
28. Srivastava, P. K., and Upadhyaya, J. S. (1977) New compounds: Potential antituberculous agents I: Alkylaryl 4-arylformamidinothi-osemicarbazones. J. Pharm. Sci. 66, 904-906.
29. National Committee for Clinical Laboratory Standards (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard, 2nd ed., NCCLS Document M27-2A, National Committee for Clinical Laboratory Standards, Wayne, PA.
30. Richardson, D. R., Tran, E. H., and Ponka, P. (1995) The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86, 4295-4306.
31. Richardson, D. R., and Baker, E. (1990) The uptake of iron and transferrin by the human malignant melanoma cell. Biochim. Biophys. Acta 1053, 1-12.
32. Richardson, D. R., and Baker, E. (1992) Intermediate steps in cellular iron uptake from transferrin. Detection of a cytoplasmic pool of iron, free of transferrin. J. Biol. Chem. 267, 21384-21389.
33. Baker, E., Richardson, D., Gross, S., and Ponka, P. (1992) Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylal-dehyde and 2-hydroxy-l-naphthylaldehyde using the hepatocyte in culture. Hepatology 15, 492-501.
34. Easmon, J., Heinisch, G., and Holzer, W. (1989) Pyridazines 47. The configuration of thiosemicarbazone derivatives of pyridazinecarbal-dehydes and alkyl pyridazinyl ketones. Heterocycles 29, 1399-1408.
35. Antonini, I., Claudi, F., Franchetti, P., Grifantini, M., and Martelli, S. (1977) Elucidation of the structure of the antineoplastic agents, 2-formylpyridine and 1-formylisochinoline thiosemicarbazones. J. Med. Chem. 20, 447-449.
36. Easmon, J., Heinisch, G., and Holzer, W. (1993) On the stereochemistry of novel biologically active diazine-derived thiosemicarbazones. Sci. Pharm 61, 3-10.
37. Rodriguez-Arguelles, M. C., Lopez-Silva, E. C., Sanmartin, J., Pelagatti, P., and Zani, F. (2005) Copper complexes of imidazole-2-, pyrrole-2- and indol-3-carbaldehyde thiosemicarbazones: Inhibitory activity against fungi and bacteria. J. Inorg. Biochem. 99, 2231-2239.
38. Jouad, E. M., Larcher, G., Allain, M., Riou, A., Bouet, G. M., Khan, M. A., and Thanh, X. D. (2001) Synthesis, structure and biological activity of nickel(II) complexes of 5-methyl 2-furfural thiosemicarbazone. J. Inorg. Biochem. 86, 565-571.
39. Lovejoy, D. B., and Richardson, D. R. (2002) Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate high anti-proliferative activity that is selective for tumor cells. Blood 100, 666-676.
40. Lober, G., and Hoffmann, H. (1990) Ambazone as a membrane active antitumor drug. Biophys. Chem. 35, 287-300.
41. Geller, K., Stutter, E., Hanschmann, H., Lober, G., Schutz, H., and Birckner, E. (1987) Ambazone interaction with phospholipid-bilayers as studied by fluorescence probe technique. Stud. Biophys. 117, 67-81.
42. Opletalova, V., Haiti, J., Patel, A., Palat, K., Jr., and Buchta, V. (2002) Ring substituted 3-phenyl-1-(2-pyrazinyl)-2-propen-1-ones as potential photosynthesis-inhibiting, antifungal and antimycobacterial agents. Farmaco 57, 135-144.
43. Opletalova, V., Pour, M., Kunes, J., Buchta, V., Silva, L., Kralova, K., Meltrova, D., Peterka, M., and Poslednikova, M. (2006) Synthesis and biological evaluation of (E)-3-(nitrophenyl)-1-(pyrazin-2-y1)prop-2-en-1-ones. Collect. Czech. Chem. Commun. 71, 44-58.
44. Baker, E., Page, M., Torrance, J., and Grady, R. W. (1985) Effect of desferrioxamine, rhodotorulic acid and cholylhydroxamic acid on transferrin and iron exchange with hepatocytes in culture. Clin. Physiol. Biochem. 3, 277-288.
45. Spellberg, B., Edwards, J., Jr., and Ibrahim, A. (2005) Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. Clin. Microbiol. Rev. 18, 556-569.
46. Chayakulkeeree, M., Ghannoum, M. A., and Perfect, J. R. (2006) Zygomycosis: The re-emerging fungal infection. Eur. J. Clin. Microbiol. Infect. Dis. 25, 215-229.
47. Greenberg, R. N., Mullane, K., van Burik, J.-A. H., Raad, L, Abzug, M. J., Anstead, G., Herbrecht, R., Langstem, A., Marr, K. A., Schiller, G., Schuster, M., Wingard, J. R., Gonzales, C. E., Revankar, S. G., Corcoran, G., Kryscio, R. J., and Hare, R. (2006) Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother. 50, 126-133.
48. Uchida, K., Yokota, N., and Yamaguchi, H. (2001) In vitro antifungal activity of posaconazole against various pathogenic fungi. Int. J. Antimicrob. Agents 18, 167-172.
49. Kaneko, T., Abe, F., Ito, M., Hotchi, M., Yamada, K., and Okada, Y. (1991) Intestinal mucormycosis in a hemodialysis patient treated with desferrioxamine. Acta Pathol. Jpn. 41, 561-566.
50. Boelaert, J. R., Van Cutsem, J., de Locht, M., Schneider, Y. J., and Crichton, R. R. (1994) Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridone chelators have no effect. Kidney Int. 45, 661-671.
51. Reed, C., Ibrahim, A., Edwards, J. E., Walot, I., and Spellberg, B. (2006) Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob. Agents Chemother. 50, 3968-3969.
52. Becker, E. M., Lovejoy, D. B., Greer, J. M., Watts, R., and Richardson, D. R. (2003) Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br. J. Pharmacol. 138, 819-830.
53. Liberia, A. E., and West, D. X. (1992) Antifungal and antitumor activity of heterocyclic thiosemicarbazones and their metal complexes: Current status. Biometals 5, 121-126.
54. Kasuga, N. C., Sekino, K., Ishikawa, M., Honda, A., Yokoyama, M., Nakano, S., Shimada, N., Koumo, C., and Nomiya, K. (2003) Synthesis, structural characterization and antimicrobial activities of 12 zinc(II) complexes with four thiosemicarbazone and two semicar-bazone ligands. J. Inorg. Biochem. 96, 298-310.
55. Kalinowski, D. S., Sharpe, P. C., Bernhardt, P. V., and Richardson, D. R. (2007) Design, synthesis and characterization of new iron chelators with anti-proliferative activity: Structure-activity relationships of novel thiohydrazone analogs. J. Med. Chem. 50, 6212-6225.
56. Bernhardt, P. V., Chin, P., Sharpe, P. C., Wang, J.-Y. C., and Richardson, D. R. (2005) Novel diaroylhydrazine ligands as iron chelators: Coordination chemistry and biological activity. J. Biol. Inorg. Chem. 10, 761-777.
57. Dunn, L. L., Suryo-Rahmanto, Y., and Richardson, D. R. (2007) Iron uptake and metabolism in the new millennium. Trends Cell Biol. 17, 93-100.
58. Kalinowski, D., Sharpe, P. C., Bernhardt, P. V., and Richardson, D. R. (2007) Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: The methyl pyrazinylketone isonicotinoyl hydrazone series. J. Med. Chem. 51, 331-344.